Top News

Amgen Completes Avidia Acquisition

Thousand Oaks-based Amgen has completed its acquisition of Mountain View-based Avidia, the firm said Tuesday afternoon. The previously announced acquisition was worth $290M. Avidia's lead product candidate is an inhibitor of interleukin 6, targeted at the treatment of inflammation and autoimmune diseases.





Latest Headlines

Browse Issues


Keep up with all of the latest Southern California high tech news via email (it's free!)

or Cancel